Neutralizing antibodies against EBV gp42 show potent in vivo protection and define novel epitopes

Epstein–Barr virus (EBV) is the first reported human oncogenic virus and infects more than 95% of the human population worldwide. EBV latent infection in B lymphocytes is essential for viral persistence. Glycoprotein gp42 is an indispensable member of the triggering complex for EBV entry into B cell...

Full description

Bibliographic Details

Published in:	Emerging Microbes and Infections
Main Authors:	Qian Wu, Ling Zhong, Dongmei Wei, Wanlin Zhang, Junping Hong, Yinfeng Kang, Kaiyun Chen, Yang Huang, Qingbing Zheng, Miao Xu, Mu-Sheng Zeng, Yi-Xin Zeng, Ningshao Xia, Qinjian Zhao, Claude Krummenacher, Yixin Chen, Xiao Zhang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Subjects:	Epstein-Barr virus glycoprotein gp42 neutralizing antibody humanized mouse model membrane fusion lymphoma
Online Access:	https://www.tandfonline.com/doi/10.1080/22221751.2023.2245920